Syndax Pharmaceuticals, Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
Syndax Pharmaceuticals, Inc. (SNDX) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $0 as of 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2022-08-08
- 2022-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2021-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $2.29M.
- 2021-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $2.29M.
- 2021-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $2.29M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 |
| 2021-09-30 | $2.29M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $2.29M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $2.29M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |